Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

275
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
275
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternative Conditioning Regimens for Hemoglobinopathy Gene Therapy: Balancing Efficacy, Toxicity, and the Next Frontier.

Blood advances·2026
Same author

Investigating the interaction of design factors on fretting and corrosion resistance in modular femoral head tapers.

Scientific reports·2026
Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026
Same author

Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.

Blood global hematology·2026
Same author

Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease.

European journal of haematology·2026
Same author

Beyond Mistrust: Diverse Biobanking Preferences Among Parents and Adolescents with Sickle Cell Disease.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Related Experiment Video

Updated: May 27, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

Senolytics restore hematopoietic stem cell function in sickle cell disease.

Aditya Barve, Adam Cornwell, Pramika Sriram

    Biorxiv : the Preprint Server for Biology
    |February 20, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Sickle Cell Disease damages bone marrow stem cells, causing dysfunction. Senolytics, like navitoclax, reversed this damage in mice, offering a new treatment strategy for sickle cell disease patients.

    More Related Videos

    Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
    08:23

    Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

    Published on: November 5, 2019

    9.7K
    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
    03:40

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

    Published on: December 8, 2023

    879

    Related Experiment Videos

    Last Updated: May 27, 2025

    A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
    07:24

    A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

    1.7K
    Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
    08:23

    Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

    Published on: November 5, 2019

    9.7K
    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
    03:40

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

    Published on: December 8, 2023

    879

    Area of Science:

    • Hematology
    • Molecular Biology
    • Gerontology

    Background:

    • Sickle Cell Disease (SCD) is linked to myeloid malignancies and hematopoietic stem cell (HSC) dysfunction.
    • Pathological stress on bone marrow is a suspected cause of SCD-related HSC issues.

    Purpose of the Study:

    • To investigate the impact of SCD on bone marrow hematopoietic stem and progenitor cells (HSPCs).
    • To explore senolytics as a therapeutic strategy for SCD-induced bone marrow dysfunction.

    Main Methods:

    • Analysis of bone marrow HSPCs from mice and individuals with SCD.
    • Assessment of cell cycle, oxidative stress, DNA damage, and senescence in HSPCs.
    • Evaluation of hematopoietic potential of human SCD HSPCs ex vivo.
    • Treatment of SCD mice with the senolytic agent ABT-263 (navitoclax).

    Main Results:

    • SCD HSPCs exhibit extended cell cycle times, oxidative stress, DNA damage, and senescence.
    • Human SCD HSPCs show impaired hematopoietic potential ex vivo.
    • SCD mice experience a significant loss of transplantable bone marrow HSPCs.
    • Treatment with ABT-263 reversed the loss of HSPCs in SCD mice.

    Conclusions:

    • SCD causes significant bone marrow HSPC dysfunction characterized by cellular stress and senescence.
    • Senolytics, specifically ABT-263, can restore bone marrow function in a mouse model of SCD.
    • Senolytics represent a promising therapeutic approach for improving bone marrow health in SCD patients and enhancing the safety of gene therapies.